CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

PURPOSE: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. METHODS: Participants with chronic pain (94% on...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, D. Max, Weitzel, Kristin W., Elsey, Amanda R., Langaee, Taimour, Gong, Yan, Wake, Dyson T., Duong, Benjamin Q., Hagen, Melanie, Harle, Christopher A., Mercado, Elvira, Nagoshi, Ying, Newsom, Kimberly, Wright, Ashleigh, Rosenberg, Eric I., Starostik, Petr, Clare-Salzler, Michael J., Schmidt, Siegfried O., Fillingim, Roger B., Johnson, Julie A., Cavallari, Larisa H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650382/
https://www.ncbi.nlm.nih.gov/pubmed/30670877
http://dx.doi.org/10.1038/s41436-018-0431-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650382/
https://www.ncbi.nlm.nih.gov/pubmed/30670877
http://dx.doi.org/10.1038/s41436-018-0431-8

Ejemplares similares